Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPAR gamma in SHRs

摘要

Gastrodin is a bioactive compound extracted from traditional Chinese medicine, Gastrodia elata Bl. It has a definite effect on reducing blood pressure in hypertensive patients. However, the mechanisms of gastrodin in lowering blood pressure still remain unclear. In this study, 4 weeks of administration of gastrodin (100mg/kg/d intraperitoneally injected) decreased the systolic blood pressure (SBP) in spontaneously hypertensive rats (SHRs) (190.2 +/- 8.9 versus 169.8 +/- 6.4, P 0.01). Among SHRs receiving gastrodin treatment, angiotensin II (Ang II) and aldosterone (ALD) in serum were significantly decreased (2022.1 +/- 53.0 versus 1528.7 +/- 93.9, 213.33 +/- 35.17 versus 179.65 +/- 20.31, and P 0.01, P 0.05, resp.) and dramatically downregulated expression of angiotensin type 1 receptor (AT1R) (4.9 +/- 0.9 versus 2.6 +/- 0.9, P 0.05) in myocardium in both mRNA and protein levels compared with their corresponding groups without gastrodin treatment. Additionally, gastrodin increased the mRNA expression (0.18 +/- 0.07 versus 0.82 +/- 0.10, P 0.01) and protein synthesis (0.40 +/- 0.10 versus 0.34 +/- 0.10, P 0.01) of peroxisome proliferator-activated receptor gamma (PPAR gamma) in myocardium tissues. Overall, our data demonstrated that gastrodin was able to decrease the SBP in SHR. Furthermore, this study showed that gastrodin intervened with the renin-angiotensin-aldosterone system (RAAS) and PPAR gamma effectively, which indicates its antihypertensive mechanism.